Do analysts rate RYM or INTS?

Intensity Therapeutics has a consensus price target of $7.00, indicating a potential upside of 70.32%. Given Intensity Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Intensity Therapeutics is more favorable than RYTHM. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RYTHM 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Intensity Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80

Do analysts rate AGFY or INTS?

Intensity Therapeutics has a consensus price target of $7.00, indicating a potential upside of 70.32%. Given Intensity Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Intensity Therapeutics is more favorable than Agrify. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Agrify 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Intensity Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80

Do analysts prefer INTS or SCLX?

Intensity Therapeutics presently has a consensus price target of $7.00, suggesting a potential upside of 70.32%. Given Intensity Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Intensity Therapeutics is more favorable than Scilex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intensity Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80 Scilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Intensity Therapeutics (INTS) Competitors

$4.11 +0.23 (+5.93%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$4.10 -0.01 (-0.24%)

As of 09/18/2026 07:39 PM Eastern

Compare

INTS vs. RYM, SCYX, AGFY, CLNN, and SCLX

Should you buy Intensity Therapeutics stock or one of its competitors? Intensity Therapeutics's main competitors and comparable companies include RYTHM (RYM), SCYNEXIS (SCYX), Agrify (AGFY), Clene (CLNN), and Scilex (SCLX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Intensity Therapeutics compare to RYTHM?

RYTHM (NASDAQ:RYM) and Intensity Therapeutics (NASDAQ:INTS) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends.

6.0% of RYTHM shares are owned by institutional investors. Comparatively, 3.7% of Intensity Therapeutics shares are owned by institutional investors. 3.5% of RYTHM shares are owned by company insiders. Comparatively, 7.6% of Intensity Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Intensity Therapeutics has a consensus price target of $7.00, indicating a potential upside of 70.32%. Given Intensity Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Intensity Therapeutics is more favorable than RYTHM.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RYTHM	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Intensity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Intensity Therapeutics has a net margin of 0.00% compared to RYTHM's net margin of -6.20%. RYTHM's return on equity of -12.57% beat Intensity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RYTHM	-6.20%	-12.57%	-2.60%
Intensity Therapeutics	N/A	-116.61%	-94.01%

In the previous week, RYTHM's average media sentiment score of 0.00 equaled Intensity Therapeutics'average media sentiment score.

Company	Overall Sentiment
RYTHM	Neutral
Intensity Therapeutics	Neutral

Intensity Therapeutics has lower revenue, but higher earnings than RYTHM. RYTHM is trading at a lower price-to-earnings ratio than Intensity Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RYTHM	$17.28M	2.83	-$33.26M	-$10.53	N/A
Intensity Therapeutics	N/A	N/A	-$11.61M	-$3.57	N/A

RYTHM has a beta of 9.44, meaning that its stock price is 844% more volatile than the broader market. Comparatively, Intensity Therapeutics has a beta of 2.76, meaning that its stock price is 176% more volatile than the broader market.

Summary

Intensity Therapeutics beats RYTHM on 8 of the 13 factors compared between the two stocks.

How does Intensity Therapeutics compare to SCYNEXIS?

Intensity Therapeutics (NASDAQ:INTS) and SCYNEXIS (NASDAQ:SCYX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, earnings, analyst recommendations, dividends and valuation.

Intensity Therapeutics presently has a consensus target price of $7.00, indicating a potential upside of 70.32%. SCYNEXIS has a consensus target price of $33.00, indicating a potential upside of 639.91%. Given SCYNEXIS's higher probable upside, analysts clearly believe SCYNEXIS is more favorable than Intensity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intensity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

SCYNEXIS has higher revenue and earnings than Intensity Therapeutics. SCYNEXIS is trading at a lower price-to-earnings ratio than Intensity Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intensity Therapeutics	N/A	N/A	-$11.61M	-$3.57	N/A
SCYNEXIS	$20.60M	2.15	-$8.61M	-$2.09	N/A

In the previous week, SCYNEXIS had 1 more articles in the media than Intensity Therapeutics. MarketBeat recorded 1 mentions for SCYNEXIS and 0 mentions for Intensity Therapeutics. Intensity Therapeutics' average media sentiment score of 0.00 equaled SCYNEXIS'saverage media sentiment score.

Company	Overall Sentiment
Intensity Therapeutics	Neutral
SCYNEXIS	Neutral

Intensity Therapeutics has a net margin of 0.00% compared to SCYNEXIS's net margin of -41.79%. SCYNEXIS's return on equity of -44.15% beat Intensity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intensity Therapeutics	N/A	-116.61%	-94.01%
SCYNEXIS	-41.79%	-44.15%	-32.61%

Intensity Therapeutics has a beta of 2.76, meaning that its stock price is 176% more volatile than the broader market. Comparatively, SCYNEXIS has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market.

3.7% of Intensity Therapeutics shares are owned by institutional investors. Comparatively, 54.4% of SCYNEXIS shares are owned by institutional investors. 7.6% of Intensity Therapeutics shares are owned by company insiders. Comparatively, 4.1% of SCYNEXIS shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

SCYNEXIS beats Intensity Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Intensity Therapeutics compare to Agrify?

Agrify (NASDAQ:AGFY) and Intensity Therapeutics (NASDAQ:INTS) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, valuation, risk and analyst recommendations.

In the previous week, Agrify's average media sentiment score of 0.00 equaled Intensity Therapeutics'average media sentiment score.

Company	Overall Sentiment
Agrify	Neutral
Intensity Therapeutics	Neutral

Intensity Therapeutics has a net margin of 0.00% compared to Agrify's net margin of -424.11%. Intensity Therapeutics' return on equity of -116.61% beat Agrify's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agrify	-424.11%	-185.90%	-72.67%
Intensity Therapeutics	N/A	-116.61%	-94.01%

Agrify has a beta of 9.96, suggesting that its stock price is 896% more volatile than the broader market. Comparatively, Intensity Therapeutics has a beta of 2.76, suggesting that its stock price is 176% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agrify	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Intensity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

6.0% of Agrify shares are held by institutional investors. Comparatively, 3.7% of Intensity Therapeutics shares are held by institutional investors. 2.2% of Agrify shares are held by insiders. Comparatively, 7.6% of Intensity Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Intensity Therapeutics has lower revenue, but higher earnings than Agrify. Intensity Therapeutics is trading at a lower price-to-earnings ratio than Agrify, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agrify	$12.26M	3.66	-$41.75M	-$22.65	N/A
Intensity Therapeutics	N/A	N/A	-$11.61M	-$3.57	N/A

Summary

Intensity Therapeutics beats Agrify on 9 of the 14 factors compared between the two stocks.

How does Intensity Therapeutics compare to Clene?

Intensity Therapeutics (NASDAQ:INTS) and Clene (NASDAQ:CLNN) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, dividends and institutional ownership.

Intensity Therapeutics presently has a consensus target price of $7.00, indicating a potential upside of 70.32%. Clene has a consensus target price of $34.00, indicating a potential upside of 681.61%. Given Clene's higher possible upside, analysts plainly believe Clene is more favorable than Intensity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intensity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Clene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

3.7% of Intensity Therapeutics shares are owned by institutional investors. Comparatively, 23.3% of Clene shares are owned by institutional investors. 7.6% of Intensity Therapeutics shares are owned by insiders. Comparatively, 28.3% of Clene shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Clene had 2 more articles in the media than Intensity Therapeutics. MarketBeat recorded 2 mentions for Clene and 0 mentions for Intensity Therapeutics. Intensity Therapeutics' average media sentiment score of 0.00 equaled Clene'saverage media sentiment score.

Company	Overall Sentiment
Intensity Therapeutics	Neutral
Clene	Neutral

Intensity Therapeutics has a net margin of 0.00% compared to Clene's net margin of -20,063.96%. Clene's return on equity of 0.00% beat Intensity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intensity Therapeutics	N/A	-116.61%	-94.01%
Clene	-20,063.96%	N/A	-137.04%

Intensity Therapeutics has a beta of 2.76, indicating that its share price is 176% more volatile than the broader market. Comparatively, Clene has a beta of 0.95, indicating that its share price is 5% less volatile than the broader market.

Intensity Therapeutics has higher earnings, but lower revenue than Clene. Clene is trading at a lower price-to-earnings ratio than Intensity Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intensity Therapeutics	N/A	N/A	-$11.61M	-$3.57	N/A
Clene	$200K	282.53	-$26.17M	-$3.50	N/A

Summary

Clene beats Intensity Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Intensity Therapeutics compare to Scilex?

Intensity Therapeutics (NASDAQ:INTS) and Scilex (NASDAQ:SCLX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

Intensity Therapeutics presently has a consensus price target of $7.00, suggesting a potential upside of 70.32%. Given Intensity Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Intensity Therapeutics is more favorable than Scilex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intensity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Scilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Intensity Therapeutics' average media sentiment score of 0.00 equaled Scilex'saverage media sentiment score.

Company	Overall Sentiment
Intensity Therapeutics	Neutral
Scilex	Neutral

Intensity Therapeutics has higher earnings, but lower revenue than Scilex. Intensity Therapeutics is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intensity Therapeutics	N/A	N/A	-$11.61M	-$3.57	N/A
Scilex	$30.25M	1.41	-$358.73M	-$49.70	N/A

Intensity Therapeutics has a net margin of 0.00% compared to Scilex's net margin of -1,414.57%. Scilex's return on equity of 0.00% beat Intensity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intensity Therapeutics	N/A	-116.61%	-94.01%
Scilex	-1,414.57%	N/A	-147.00%

Intensity Therapeutics has a beta of 2.76, meaning that its share price is 176% more volatile than the broader market. Comparatively, Scilex has a beta of 1.65, meaning that its share price is 65% more volatile than the broader market.

3.7% of Intensity Therapeutics shares are held by institutional investors. Comparatively, 69.7% of Scilex shares are held by institutional investors. 7.6% of Intensity Therapeutics shares are held by insiders. Comparatively, 4.5% of Scilex shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Intensity Therapeutics beats Scilex on 10 of the 14 factors compared between the two stocks.

Get Intensity Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INTS vs. The Competition

Export

Metric	Intensity Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$13.42M	$12.47B	$7.24B	$13.19B
Dividend Yield	N/A	2.64%	2.57%	12.81%
P/E Ratio	-1.15	653.41	214.59	20.89
Price / Sales	N/A	753.62	646.01	89.45
Price / Cash	N/A	86.36	76.25	51.42
Price / Book	0.83	10.53	10.46	6.33
Net Income	-$11.61M	$2.82B	$3.49B	$358.33M
7 Day Performance	2.24%	1.69%	0.59%	1.12%
1 Month Performance	-2.14%	0.83%	-2.01%	-2.67%
1 Year Performance	-33.71%	3.90%	18.09%	6.01%

Intensity Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INTS Intensity Therapeutics	3.2855 of 5 stars	$4.11 +5.9%	$7.00 +70.3%	-31.5%	$13.42M	N/A	N/A	2,021	Short Interest Decrease Gap Down
RYM RYTHM	0.428 of 5 stars	$23.64 -0.8%	N/A	N/A	$51.93M	$17.28M	N/A	140	Gap Down High Trading Volume
SCYX SCYNEXIS	2.1677 of 5 stars	$4.91 -4.7%	$33.00 +572.1%	-48.9%	$51.24M	$20.60M	N/A	60
AGFY Agrify	N/A	$23.83 -9.2%	N/A	-43.2%	$47.73M	$12.26M	N/A	140	High Trading Volume
CLNN Clene	1.6282 of 5 stars	$3.72 +2.8%	$33.25 +793.8%	-31.2%	$46.51M	$200K	N/A	100

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INTS) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Intensity Therapeutics (INTS) Competitors

INTS vs. RYM, SCYX, AGFY, CLNN, and SCLX

How does Intensity Therapeutics compare to RYTHM?

Summary

How does Intensity Therapeutics compare to SCYNEXIS?

Summary

How does Intensity Therapeutics compare to Agrify?

Summary

How does Intensity Therapeutics compare to Clene?

Summary

How does Intensity Therapeutics compare to Scilex?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INTS vs. The Competition

Intensity Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Intensity Therapeutics (INTS) Competitors

INTS vs. RYM, SCYX, AGFY, CLNN, and SCLX

How does Intensity Therapeutics compare to RYTHM?

Do institutionals & insiders have more ownership in RYM or INTS?

Do analysts rate RYM or INTS?

Is RYM or INTS more profitable?

Does the media favor RYM or INTS?

Which has better earnings and valuation, RYM or INTS?

Which has more risk and volatility, RYM or INTS?

Summary

How does Intensity Therapeutics compare to SCYNEXIS?

Do analysts recommend INTS or SCYX?

Which has preferable earnings & valuation, INTS or SCYX?

Does the media refer more to INTS or SCYX?

Is INTS or SCYX more profitable?

Which has more risk and volatility, INTS or SCYX?

Do institutionals and insiders believe in INTS or SCYX?

Summary

How does Intensity Therapeutics compare to Agrify?

Does the media prefer AGFY or INTS?

Is AGFY or INTS more profitable?

Which has more volatility & risk, AGFY or INTS?

Do analysts rate AGFY or INTS?

Do insiders and institutionals believe in AGFY or INTS?

Which has better earnings & valuation, AGFY or INTS?

Summary

How does Intensity Therapeutics compare to Clene?

Do analysts rate INTS or CLNN?

Do institutionals & insiders have more ownership in INTS or CLNN?

Does the media refer more to INTS or CLNN?

Is INTS or CLNN more profitable?

Which has more risk and volatility, INTS or CLNN?

Which has stronger earnings and valuation, INTS or CLNN?

Summary

How does Intensity Therapeutics compare to Scilex?

Do analysts prefer INTS or SCLX?

Does the media prefer INTS or SCLX?

Which has higher valuation & earnings, INTS or SCLX?

Is INTS or SCLX more profitable?

Which has more risk and volatility, INTS or SCLX?

Do institutionals and insiders hold more shares of INTS or SCLX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INTS vs. The Competition

Intensity Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools